Some of the $20 million that the US startup ImmusanT raised late last year in a Series A financing is being put to use with the start of an expanded international clinical programme for Nexvax2, its ground-breaking therapeutic vaccine for coeliac disease.One of the new placebo-controlled Phase I trials will see around 84 patients enrolled across four sites in Australia and New Zealand, in which induction of tolerance in individuals on a gluten-free diet will be assessed at multiple ascending doses.
The second new trial, in around 30 adults at four sites in the US, will look at safety, tolerability and...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
